# US 10,307,383 B2 · Cosmetic composition for preventing or ameliorating hypersensitive skin comprising cedrol or derivatives thereof, or pharmaceutically acceptable salts thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,383 B2
- Document ID: US10307383B2
- Status: Granted
- Kind: B2
- Application number: 15/945,601
- Filed: 2018-04-04
- Published: 2018-10-11
- Granted: 2019-06-04
- Earliest claimed: 2017-04-05
- Assignees: University of Seoul Industry Cooperation Foundation
- Applicants: University of Seoul Industry Cooperation Foundation
- Inventors: Ha Won Kim; Dong Hee Lee
- Web page: https://patentgrep.com/patent/US10307383B2

## CPC

- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/015: carbocyclic
- A61K 31/075: Ethers or acetals
- A61K 31/12: Ketones
- A61K 31/215: of carboxylic acids
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.

## Claims

### Claim 1

A method of alleviating skin irritation in a subject, comprising:
administering to the subject an effective amount of one or more compounds selected from the group consisting of the compounds represented by the following formulas 1˜3 or a pharmaceutically acceptable salt thereof as an active ingredient,
wherein the skin irritation is due to psoriasis; and
wherein the skin irritation is one or more selected from the group consisting of keratosis, skin flare, skin pain and skin hemorrhage spots:

### Claim 2 (depends on 1)

The method of alleviating skin irritation according to claim 1, wherein the psoriasis is mediated by interleukin-17.